{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-25-000106","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.475968+00:00","generated_at":"2026-05-17T20:44:01.424578+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31","bullets":["Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.","Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.","Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.","Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.","Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-25-000106","json":"https://secwatch.observer/filing/0001606498-25-000106.json","markdown":"https://secwatch.observer/filing/0001606498-25-000106.md","text":"https://secwatch.observer/filing/0001606498-25-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/0001606498-25-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/avns-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:44:01.424578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}